title: Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in Taiwan.
abstract: OBJECTIVE
  To evaluate treatment outcomes and healthcare resource use with conventional amphotericin B therapy for invasive fungal infections (IFIs).
  
  
  METHODS
  A prospective observational study in hospitalized adult patients receiving amphotericin B treatment was undertaken at four hospitals in Taiwan. Patients were observed from the start of therapy to hospital discharge.
  
  
  RESULTS
  A total of 108 patients (October 2000 to April 2002) were included in the study. Proven or probable IFIs as defined by the EORTC/MSG criteria were the reasons for the initiation of amphotericin B in 35.2% of the sample. A total of 24.1% patients developed nephrotoxicity (NT) (defined as a 50% increase in the baseline serum creatinine and achieving a peak of at least 2.0 mg/dL). Treatment of proven/probable IFIs [odds ratio (OR) = 4.16, 95% confidence interval (CI) = 1.61-10.75] was a significant predictor of the development of NT. The in-hospital mortality rate was 38.0%. Proven/probable IFIs (OR = 6.93, 95% CI = 2.62-18.29) and the development of NT (OR = 3.68, 95% CI = 1.22-11.04) were independent predictors of in-hospital mortality. For patients alive at discharge, those with NT had a trend of longer hospital stay compared with patients who had not developed NT (mean, 49.3 +/- 18.2 versus 29.3 +/- 22.3 days, P = 0.069). For patients who died, those who had developed NT died sooner (15.5 +/- 16.7 versus 33. 8 +/- 26.9 days, P = 0.0004).
  
  
  CONCLUSIONS
  NT was associated with accelerated mortality and increased hospital stay for patients who survived. Using amphotericin B carefully or the use of antifungal agents with less potential for NT might improve patient outcomes.
authors.affiliation: Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, Taiwan 100. ycc@ha.mc.ntu.edu.tw
authors.forename: Chien-Yuan
authors.initials: CY
authors.lastname: Chen
authors.forename: Ritesh N
authors.initials: RN
authors.lastname: Kumar
authors.forename: Yin-Hsun
authors.initials: YH
authors.lastname: Feng
authors.forename: Chao-Hung
authors.initials: CH
authors.lastname: Ho
authors.forename: Jie-Yu
authors.initials: JY
authors.lastname: You
authors.forename: Chi-Chou
authors.initials: CC
authors.lastname: Liao
authors.forename: Chiung-Hui
authors.initials: CH
authors.lastname: Tseng
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Mavros
authors.forename: William C
authors.initials: WC
authors.lastname: Gerth
authors.forename: Yee-Chun
authors.initials: YC
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy* / Q000401:mortality; D011446:Prospective Studies; D013624:Taiwan; D016896:Treatment Outcome
chemical_list: D000666:Amphotericin B; D003404:Creatinine